Influence of development and joint pathology on stromelysin enzyme activity in equine synovial fluid

P A J Brama, J M TeKoppele, B Beekman, B van El, A Barneveld, P R van Weeren

Abstract

Objective—To investigate the role of stromelysin (MMP-3) activity in synovial fluid (SF) at different stages of development and in common joint disorders in the horse.

Methods—Stromelysin activity was determined with a fluorogenic enzyme activity assay in SF of normal joints of fetal, juvenile and adult horses, and in SF of horses suffering from the developmental orthopaedic disease osteochondrosis (OC) or osteoarthritis (OA). Additionally, MMP-3 activity was expressed as a ratio of previously reported general MMP activity in the same SF samples.

Results—The levels of active stromelysin were 30-fold to 80-fold higher in SF from fetal horses than in SF from juvenile and mature animals. Juvenile horses (5 and 11 months of age) showed a twofold to threefold higher stromelysin activity than adult horses (p < 0.05). In OC joints, stromelysin activity was not significantly different from the activity in normal, age matched, control joints. In OA joints the activity was about four times higher than in normal joints (p < 0.001). The ratio MMP-3 activity/general MMP activity did not change with age in normal, healthy joints. This ratio was more then twofold increased in OA joints compared with normal joints, indicating selective up-regulation of gene expression or activation of proMMP-3, or both, in OA pathology.

Conclusions—The significantly higher stromelysin activity in young individuals parallels the higher metabolic activity occurring at rapid growth and differentiation at early age. In OC, MMP-3 mediated matrix degradation appears to be not different from normal joints. The increased stromelysin activity in OA joints is in agreement with pathological matrix degradation. In these joints MMP-3 activity is selectively increased compared with normal joints.

(MM)P-3 has been implicated to play a pivotal part in joint pathology. Its synthesis by chondrocytes and synoviocytes can be induced by inflammatory mediators like interleukin 1. Highly increased activities of MMP-3 have been found in arthritic cartilage, synovium, and synovial fluid (SF), suggesting a role for this enzyme in matrix degradation. The other stromelysins, MMP-10 and -11, were shown to be absent or present in low levels only in joint tissues.

In this study a selective fluorogenic assay is used to measure MMP-3 activity in the SF of fetal, juvenile and adult horses, and in the SF of joints affected by osteochondrosis (OC) or osteoarthritis (OA). The objective of this study was to focus specifically on MMP-3 activity during development, in two common equine joint disorders and to relate presented findings with previously reported general MMP activity in the same samples.

Methods

Experimental design

Stage of development

SF from normal metacarpophalangeal joints of equine fetuses (n=10), 5 month old foals (n=10), 11 month old foals (n=10), and adult horses (n=10, age (mean (SD)) 7.3 (1.8) years, range 4–10 years) was obtained (2–4 ml) within four hours after death, centrifugated
(10 000 x g, 15 minutes), and the resulting cell free supernatant was frozen at −20°C until further analysis. Similar collection procedures were performed for normal tarsocrural joints of 5 month old (n=10) and 11 month old (n=6) foals. No effect of collection time (up to 12 hours) was observed on MMP activity.

Joint disorders
SF was collected from 10 adult horses (age mean (SD) 8.2 (2.3) years, range 4–11 years; age matched with the above mentioned control animals; p > 0.05), with evidence of OA of the metacarpophalangeal joint and from 10, 5 month old foals with OC (as reported elsewhere).5

MMP−3 ACTIVITY ASSAY
After 10-fold dilution in buffer A (50 mM TRIS (pH 7.5), 150 mM NaCl, 5 mM CaCl2, 1 mM ZnCl2, 0.01% Brij-35) MMP-3 activity in SF was measured as described elsewhere11 12: 90 µl diluted SF was added to 22.5 µl of the selective MMP inhibitor CP138521 (2.4 µM; Pfizer Central Research, Groton, CT, USA), 22.5 µl EDTA free Complete (a mixture of non-MMP inhibitors; 2 tablets in 2.5 ml buffer A; Boehringer Mannheim, Germany), and 45 µl of the substrate TNO003-F (4 µM).11 12 Incubations were performed in a Cytofluor II (λex = 360 nm, λem = 490 nm; PerSeptive Biosystems). Incubation time was 3.5 hours and consisted of 20 fluorescence measurements. The initial velocity of substrate turnover (linear increase in fluorescence over time) was used as a measure for enzyme activity. The concentration of active MMP-3 in the synovial fluid was calculated using a calibration curve of MMP-3 (human recombinant MMP-3, Pfizer, Central Research, Groton, CT, USA) spiked to SF.11 12

Previously reported general MMP activities of the same SF samples were used to present the ratio of MMP-3/general MMP activity calculated individually for each SF sample.5

STATISTICAL ANALYSIS
Data are presented as the mean (SEM). Differences between groups were tested by one way analysis of variance. Fisher's least significant difference multiple comparisons test of the means was applied as post hoc test. Differences were considered significant when p < 0.05.

Results
STAGE OF DEVELOPMENT
Extremely high stromelysin activity (30-fold to 80-fold higher than in normal juvenile and adult joints) was observed in fetal metacarpophalangeal joints. After birth, stromelysin activity gradually declined in SF from normal joints (5 months > 11 months > adult; fig 1A). Consistent with these findings, MMP-3 activity in SF of osteoarthritic adult metacarpophalangeal joints was almost four-fold higher than in the SF of normal adult metacarpophalangeal joints (fig 1A).

Figure 1 (A) MMP-3 activity (nM; mean (SEM)) in SF of the normal fetal, normal juvenile (5 and 11 months), normal adult (mean age 7.3 years, range 4–10 year), and osteoarthritic (mean age 8.2 years, range 4–11 year) equine metacarpophalangeal joints. (B) MMP-3 activity (nM; mean (SEM)) in SF of the normal juvenile (5 and 11 months), and osteochondrotic (5 months) equine tarsocrural joints. MMP=matrix metalloproteinase; N=normal joints; NS=not significant; OA=osteoarthritic joints; OC=osteochondrotic joints; SF=synovial fluid.
Figure 2 The ratio of MMP-3 activity/general MMP activity in SF of the metacarpophalangeal joint. Normal adult set at 1. * p<0.05 versus normal adult.

MMP-3 activity compared with activity of other MMPs

Figure 2 gives the ratio of MMP-3 activity and general MMP activity for the metacarpophalangeal joint. In normal joints, at all ages, a ratio MMP-3/general MMP identical to one was observed. Similar findings were done for normal tarsocentral joints at the age of 5 months (0.99 (0.15)) and 11 months (0.86 (0.15)). This indicates that MMP-3 gene expression, activation of proenzyme, or inhibition by TIMP is not different from general MMP activity during development. In OA joints the ratio MMP-3/general MMP is twofold higher than in normal joints (p<0.01).

Discussion

This study shows a gradual decrease in stromelysin activity during maturation starting with very high activities in the fetal joint. The amounts of active MMP-3 in both the metacarpophalangeal and tarsocentral joint fluid were similar, which suggests that the age related decline in MMP-3 activity can be considered a systemic effect—that is, the same for all synovial joints in an individual animal. In fetal metacarpophalangeal joints MMP-3 activity was as much as 80-fold higher in the adult horse. These very high activities are consistent with the rapid tissue turnover in the fetal joint. The influence of developmental stage on MMP activity emphasises the need for age matched controls when studying pathological conditions, especially when growing individuals are concerned such as in OC or other developmental orthopaedic diseases.

Early diagnosis of OA is a major problem, both in human and veterinary medicine. In the horse, Clegg et al. showed that MMP-2 and MMP-9 activities are significantly increased in both aseptic and septic joint diseases. Balkman et al. showed that MMP-3 mRNA expression is low in normal cartilage and synovial membrane, but increased in arthritic cartilage. Recently, we found a twofold higher general MMP activity in osteoarthritic SF than in controls. In this study we show that the activity of stromelysin, is even more increased (fourfold higher).

This study showed that specific MMP-3 activity was not significantly higher in OC tarsocentral joints when compared with age matched control joints. Also, general MMP activity was not increased as shown previously in the same SF samples. This again is an indication that metalloproteinase mediated matrix destruction is not of major importance in OC.

During growth, development and maturation, the ratio MMP-3/general MMP activity did not change in normal, healthy joints. In contrast, this ratio was more then twofold increased in OA joints compared with normal joints, indicating selective upregulation of gene expression and/or activation of proMMP-3 and/or inhibition by TIMP in OA pathology.

It is concluded that stromelysin activity in equine SF reflects physiological and pathological tissue turnover of cartilage. The activity of MMP-3 is more outspoken in pathological tissue degradation as occurs in OA than in physiological turnover during maturation.

The authors would like to thank I Otterness and P Mitchell from Pfizer Central Research, Groton, CT, USA for kindly providing the selective MMP inhibitor (CP 138521) and human recombinant MMP-3.

Influence of development and joint pathology on stromelysin enzyme activity in equine synovial fluid

P A J Brama, J M TeKoppele, B Beekman, B van El, A Barneveld and P R van Weeren

doi: 10.1136/ard.59.2.155

Updated information and services can be found at:
http://ard.bmj.com/content/59/2/155

These include:

References
This article cites 15 articles, 3 of which you can access for free at:
http://ard.bmj.com/content/59/2/155#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
California and bone (725)
Degenerative joint disease (4641)
Musculoskeletal syndromes (4951)
Osteoarthritis (931)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/